中迪投資(000609.SZ)連續2個漲停 擬收購山東育達健康為跨界投資存業務整合失敗的風險
格隆匯11月24日丨中迪投資(000609.SZ)公佈,公司股票於2019年11月21日、11月22日連續兩個交易日收盤價格漲幅偏離值累計超過20%,根據《深圳證券交易所交易規則》的有關規定,屬於股票交易異常波動的情況。
目前,公司擬以支付現金方式收購山東育達健康科技股份有限公司100%股權的交易事項尚處於初步籌劃階段,此次交易的具體情況需視公司對標的公司的盡職調查、審計、評估及交易各方協商的結果確定,故此次交易是否構成重大資產重組及此次交易的具體方案尚存在不確定性,此次交易也存在可能失敗的風險。
截至2019年9月30日,公司資產負債率為61.31%。鑑於此次交易價格未確定,尚存在交易無法達成的履約風險。
此次交易為跨界投資,公司未組建有標的公司行業領域的專業人員團隊,尚存在業務整合失敗的風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.